| Bioactivity | Lifirafenib (BGB-283) maleate is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively[1]. |
| Target | IC50: 23 nM (recombinant BRafV600E ), 29 nM (EGFR) |
| Name | Lifirafenib maleate |
| CAS | 1854985-74-2 |
| Formula | C25H17F3N4O3.3/2C4H4O4 |
| Molar Mass | 652.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tang Z, et al. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14(10):2187-97. |
Lifirafenib maleate
CAS: 1854985-74-2 F: C25H17F3N4O3.3/2C4H4O4 W: 652.53
Lifirafenib (BGB-283) maleate is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for r
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.